1-10 of 10
Katharina Blatt, M.Sc.
Close
Sort by
Journal Articles

The Leukemic Stem Cell (LSC) in Ph + CML Is a CD34 + /CD38 − /Lin − Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

Harald Herrmann, M.D., Irina Sadovnik, M.Sc., Sabine Cerny-Reiterer, D.V.M., Katharina Blatt, M.Sc., Viviane Ghanim, M.D., Susanne Herndlhofer, Gregor Hoermann, M.D., Thomas Rülicke, D.V.M., Michael Willmann, D.V.M., Gerlinde Mitterbauer-Hohendanner, M.D., Matthias Mayerhofer, M.D., Wolfgang R. Sperr, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 961.
https://doi.org/10.1182/blood.V118.21.961.961
Published: 2011
Journal Articles

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

Viviane Ghanim, M.D., Harald Herrmann, MD, Emir Hadzijusufovic, DVM, Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Karina Schuch, Sabine Cerny-Reiterer, D.V.M., Irina Mirkina, PhD, Gerwin Heller, PhD, Sabine Zöchbauer-Müller, MD, Heidrun Karlic, PhD, Winfried F Pickl, MD, Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 3457.
https://doi.org/10.1182/blood.V118.21.3457.3457
Published: 2011
Journal Articles

5-Azacytidine and Decitabine Induce Demethylation and Re-Expression of FAS (CD95) and Promote Apoptosis in Neoplastic Cells in Acute Myeloid Leukemia (AML),

Heidrun Karlic, PhD, Rene Reitermaier, Viviane Ghanim, MD, Harald Herrmann, MD, Roman Thaler, M.Sc. PhD, Silvia Spitzer, Franz Varga, PhD, Irina Sadovnik, M.Sc., Katharina Blatt, M.Sc., Felix Keil, MD, Peter Valent, M.D., Michael Pfeilstöcker, MD
Journal: Blood
Blood (2011) 118 (21): 3463.
https://doi.org/10.1182/blood.V118.21.3463.3463
Published: 2011
Journal Articles

Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML,

Harald Herrmann, M.D., Katharina Blatt, M.Sc., Junwei Shi, Amy R. Rappaport, Karoline V. Gleixner, M.D., Sabine Cerny-Reiterer, D.V.M., Barbara Peter, D.V.M., Eric Wang, Wolfgang R. Sperr, M.D., James E. Bradner, MD, Scott W. Lowe, Ph.D., Christopher R. Vakoc, M.D., Ph.D., Johannes Zuber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 3484.
https://doi.org/10.1182/blood.V118.21.3484.3484
Published: 2011
Journal Articles

Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis,

Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Barbara Peter, D.V.M., Emir Hadzijusufovic, DVM, Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 3497.
https://doi.org/10.1182/blood.V118.21.3497.3497
Published: 2011
Journal Articles

The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release

Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Gabriele Stefanzl, Emir Hadzijusufovic, DVM, Catherine Dutreix, Stefan H Gross, Johannes L Roesel, Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 1417.
https://doi.org/10.1182/blood.V118.21.1417.1417
Published: 2011
Journal Articles

The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML

Karoline V. Gleixner, M.D., Harald Herrmann, M.D., Katharina Blatt, M.Sc., Winfried F Pickl, MD, Marina Konopleva, MD, PhD, Gahininath Y Bharate, Michael Andreeff, M.D., Ph.D., Hiroshi Maeda, MD, Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 4414.
https://doi.org/10.1182/blood.V118.21.4414.4414
Published: 2011
Journal Articles

Expression of the CAMPATH-1 Antigen (CD52) on CD34+/CD38- Progenitor Cells in Patients with 5q- MDS and in a Subset of AML

Katharina Blatt, M.Sc., Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Susanne Herndlhofer, Wolfgang R. Sperr, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2011) 118 (21): 1728.
https://doi.org/10.1182/blood.V118.21.1728.1728
Published: 2011
Journal Articles

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.

Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Susanne Herndlhofer, Hermine Agis, M.D., Werner Rabitsch, M.D., Berthold Streubel, M.D., Gerlinde Mitterbauer-Hohendanner, M.D., Wolfgang R. Sperr, M.D., Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2010) 116 (21): 3382.
https://doi.org/10.1182/blood.V116.21.3382.3382
Published: 2010
Journal Articles

Identification of Novel Surface Markers and Targets In Neoplastic Stem Cells In AML and CML: a Flow-Gene-Flow Screen Approach.

Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Irina Sadovnik, M.Sc., Viviane Winter, M.D., Katharina Blatt, M.Sc., Werner Rabitsch, M.D., Wolfgang R. Sperr, M.D., Elena De Angelis, Ph.D., Steve Holmes, Ph.D., Peter Valent, M.D.
Journal: Blood
Blood (2010) 116 (21): 1575.
https://doi.org/10.1182/blood.V116.21.1575.1575
Published: 2010